Stock Analysis of Acasti Pharma Inc (ACST) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ACST
Close 2.69
Change -0.070 / 2.53 %
Volume 15108.00
Vol Change 9794.00 / 184.31 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBearish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index No Significant Stability


Fundamental View of Acasti Pharma Inc
PE (TTM)

-149.97

Very Poor
Price / Book

82.27

Very Poor
Price / Sales

-185166.03

Very Poor
Piotroski F Score

3.0

Not Good
Market Cap

25284.39 K

Enterprise Value

-2515.61 K

ROA (TTM)

-46.66

Very Poor
ROE (TTM)

-54.86

Very Poor
Net Margin (TTM)

123465

Excellent
Revenue

100.00 %

0
Net Profit

332.11 %

-42429.00 K
Debt to Equity

0.0011

Excellent
Altman Z Score

-2.52

Very Poor
Quick Ratio

0

Poor
Cash Ratio

8.18

Excellent


Highs/Lows of Acasti Pharma Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week2.76 2.54 % 1.74 % 2.95992.6415-May-2415-May-24
Two Week2.96 9.12 % 2.54 % 3.052.6407-May-2415-May-24
One Month3.1899 15.67 % 6.94 % 3.172.6418-Apr-2415-May-24
Three Month3.3 18.48 % 6.77 % 3.592.6422-Feb-2415-May-24
Six Months2.17 23.96 % 16.82 % 3.591.9822-Feb-2417-Jan-24
One year3.0006 10.35 % 26.72 % 3.8341.7205-Jul-2322-Sep-23
Two year5.808 53.68 % 36.16 % 5.041.7223-Jan-2322-Sep-23
Five year41.0448 93.45 % 87.03 % 5.040.3423-Jan-2315-Dec-22
Ten year451.2 99.40 % 183.65 % 585.60.3409-Jul-1415-Dec-22


Technical View of Acasti Pharma Inc
RSI

35.76

Neutral
MACD

-0.114

Bearish
ADX

19.12

Neutral
Super Trend

3.20

Mild Bearish
Williams %R

-89.43

Mild Bullish
CCI

-105.31

Mild Bullish


EMA 5

2.74

Mild Bearish
EMA 15

2.82

Strong Bearish
EMA 50

2.99

Strong Bearish
EMA 100

2.93

Mild Bearish
SMA 100

2.96

Whipsaw
SMA 200

2.62

Mild Bullish
SMA 5 / 20

2.74 / 2.83

Mild Bearish
SMA 15 / 50

2.81 / 3.15

Strong Bearish
SMA 50 / 200

3.15 / 2.62

Mild Bullish




Charts of Acasti Pharma Inc


Returns of Acasti Pharma Inc with Peers
Period / StockACSTBIAFMTCRTXMD
1 Week-2.54%11.56%2.18%2.88%
1 Mth-15.67%-20.14%2.43%15.05%
3 Mth-18.48%48.00%2.41%-5.73%
6mth23.96%54.17%39.42%-26.71%
1 Year-10.35%21.31%23.70%-50.46%
2 Year-53.68%--85.36%-30.97%
5 Years-93.45%---99.97%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Acasti Pharma Inc with Peers
Ratio / StockACSTBIAFMTCRTXMD
PE-149.97-2.37-0.644-3.61
P/B82.271.930.5361.03
ROA-46.66-68.30-58.14-18.12
ROE-54.86-81.46-83.21-28.47
Debt To Equity0.00110.0950.2460.050
Revenue0
100.00 % 		321489
6593.50 % 		0
% 		69366.00 K
0.853 %
Net Income-42429.00 K
332.11 % 		-7238.43 K
11.23 % 		-62207.00 K
66.76 % 		68307.00 K
39.01 %


Technicals of Acasti Pharma Inc with Peers
Technical / StockACSTBIAFMTCRTXMD-
ADX19.1221.1214.3224.72
CMF-0.266-0.1440.5650.155
MFI18.8840.7486.6268.11
RSI35.7649.5857.1259.34
MACD Abv SignalFalseTrueTrueTrue
Price Above 50 MAFalseFalseTrueTrue-
Price Above 200 MATrueTrueTrueFalse-


About : Acasti Pharma Inc

Address : 3009 boulevard de la Concorde East, Laval, QC, Canada, H7E 2B5
Tel : 450-687-2262
URL : https://www.acastipharma.com
Code : ACST, ISIN : CA00430K8730, Exchange : NASDAQ, Country : USA
Fiscal Year End : March
IPO date : 06_May_2011

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.


Note : All Data Generated at the End of Trading Hours (EOD Data)